Fig. 3: Q1–Q3 make the quartile ranks to which outcomes were assigned.
From: European LeukemiaNet criteria for safety and efficacy evaluation of new drugs for myelofibrosis
Q1 includes top-ranked outcomes, namely the most relevant ones.
Fig. 3: Q1–Q3 make the quartile ranks to which outcomes were assigned. | Blood Cancer Journal
